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Abstract
Small pulmonary nodules are most often managed by surveillance imaging with chest 
computed tomography (CT), but the optimal frequency and duration of surveillance are 
unknown. The Watch the Spot Trial is a multi-center, pragmatic, comparative effectiveness trial 
with cluster randomization by hospital or health system that compares more vs. less intensive 
strategies for active surveillance of small pulmonary nodules. The study plans to enroll 
approximately 35,200 patients with a small pulmonary nodule that is newly detected on chest 
CT, either incidentally or by screening. Study protocols for more and less intensive surveillance 
were adapted from published guidelines. The primary outcome is the percentage of cancerous 
nodules that progress beyond American Joint Committee on Cancer 7th edition (AJCC 7) stage 
T1aN0M0. Secondary outcomes include patient-reported anxiety and emotional distress, 
nodule-related health care utilization, radiation exposure, and adherence with the assigned 
surveillance protocol. Distinctive aspects of the trial include: (1) the pragmatic integration of 
study procedures into existing clinical workflow; (2) the use of cluster-randomization by 
hospital or health system; (3) the implementation and evaluation of a system-level intervention 
for protocol-based care; (4) the use of highly efficient, technology-enabled methods to identify 
and (passively) enroll participants; (5) reliance on data collected as part of routine clinical care, 
including data from electronic health records and state cancer registries; (6) linkage with state 
cancer registries for complete ascertainment of the primary study outcome; and (7) intensive 
engagement with a diverse group of patient and non-patient stakeholders in the design and 
execution of the study.
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Pulmonary nodules are commonly identified on chest computed tomography (CT) scans, either 
as an incidental finding or by screening.(1, 2) While the majority of nodules are benign and 
harmless, up to 5% prove to be lung cancer.(3) It is important to identify cancerous nodules 
promptly because localized stage lung cancer can be treated and potentially cured. In the 
absence of suspicious features like spiculation, the standard of care for the management of 
most small pulmonary nodules is surveillance imaging to identify growth that is highly 
suggestive of malignancy, but evidence for the optimal frequency and duration of nodule 
surveillance is lacking. Furthermore, while professional societies have published national 
guidelines and other recommendations for lung nodule surveillance,(4-9) adherence to 
published recommendations is variable.(10-12) Ideally, management should maximize early 
diagnosis of individuals with cancerous nodules, while minimizing unnecessary testing of 
patients with nodules that are benign. The purpose of the Watch the Spot pragmatic trial is to 
compare the effects of more vs. less intensive surveillance imaging of small pulmonary nodules 
measuring ≤15 mm on a range of outcomes of importance to patients. 
Methods
The study is an unblinded, cluster-randomized, pragmatic, non-inferiority, comparative 
effectiveness trial of more intensive vs. less intensive CT surveillance of patients found to have 
a small pulmonary nodule (Figure 1). The study employs cluster randomization at the hospital 
or health system level to assign participants, through the institution where they receive care, to 
a more intensive or less intensive surveillance strategy. Approximately 35,200 individuals with 
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small nodules will be enrolled over a 28-month period and followed for a minimum of 2 years 
to assess a broad range of stakeholder-prioritized outcomes that correspond to the study aims:
Aim 1. Among individuals with small pulmonary nodules identified either incidentally or by 
screening, compare the percentage of cancerous nodules that progress beyond American 
Joint Committee on Cancer 7th edition (AJCC 7) stage T1aN0M0 after more vs. less intensive 
surveillance imaging.(13) We hypothesize that less intensive surveillance will be non-inferior 
to more intensive surveillance, i.e. it will not result in a greater percentage of cancerous 
nodules diagnosed at a more advanced stage.
Aim 2a. Compare patient-reported outcomes of emotional distress, anxiety, general health 
status and satisfaction with the evaluation process. 
Aim 2b. Compare provider-reported outcomes of knowledge, attitudes and beliefs about 
guidelines and practices for lung nodule evaluation, and provider satisfaction with the 
surveillance protocol and evaluation process. 
Aim 3. Compare health care resource utilization and effective radiation doses received. 
Aim 4. Compare patient and physician adherence to the recommended protocols for CT 
surveillance, and radiology department adherence to use of low radiation-dose techniques 
for screening and follow-up imaging. 
The study is funded by the Patient-Centered Outcomes Research Institute (PCORI) through its 
program in Pragmatic Clinical Studies (PCS-1403012653) and registered on ClinicalTrials.gov 
(NCT02623712). 
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Study Design and Rationale
As a pragmatic trial,(14) the study compares options for CT surveillance in diverse settings and 
in the context of usual clinical practice. The overarching goal of the pragmatic design is to 
integrate study procedures into existing clinical workflow to the greatest extent possible. As a 
comparative effectiveness trial, the study compares two alternatives in order to determine 
which one works best, for whom, and under what circumstances.(15) Designed and executed in 
close partnership with patient and non-patient stakeholders, the study outcomes are patient-
centered and reflect the explicitly stated values and preferences of all stakeholders.(16)
The study will establish linkages to data from state cancer registries to ascertain the 
primary outcome, the percentage of cancerous nodules that progress beyond AJCC 7 stage 
T1aN0M0. In addition, by surveying participants via Internet or mail using clinically validated 
questionnaires, the study will compare patient-reported outcomes of emotional distress, 
anxiety, general health status and satisfaction with the evaluation process. Using data from 
electronic health records (EHR), the study will compare the two arms for resource utilization, 
effective radiation doses received and adherence to the recommended protocols for CT 
surveillance using low radiation-dose techniques.
Settings
Study participants are identified, enrolled and followed at 14 health care delivery organizations 
(Table 1), each of which agreed to accept randomized assignment to one of the two protocols 
for surveillance of incidentally detected pulmonary nodules. Seven of 14 organizations also 
agreed to randomized assignment for the surveillance of screening-detected nodules; the other 
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sites had recently implemented the Lung CT Screening Reporting & Data System (Lung-RADSTM) 
and were not willing to accept randomized assignment to a more intensive surveillance 
protocol for nodules detected by screening. Willingness to be randomized for surveillance of 
screening-detected nodules was established prior to randomization. The multicenter design 
aimed to provide geographic, socioeconomic, and ethnic and racial diversity, and the 
participating health care organizations span the spectrum of U.S. health care delivery models. 
In addition, the settings include endemic areas for mycoses that are common causes of benign 
nodules, such as coccidioidomycosis and histoplasmosis. 
Cluster Randomization
The study employs cluster randomization because the interventions could only be feasibly and 
consistently applied at the level of the health care system, i.e. all enrolled patients at any given 
hospital/health system will receive the same set of recommendations for follow-up.(17) 
Randomization at the level of individual patients was judged to be impractical for 
implementation, potentially confusing to providers and detrimental to patient care.
Random assignment by computer program to one of the two intervention groups was 
performed at the hospital level for the 11 medical centers at Kaiser Permanente Southern 
California (KPSC) and at the health system level for 13 other sites, by using matching (18, 19) 
and re-randomization.(20) Optimal matching divided 24 sites (clusters) into 12 pairs to minimize 
differences in the potential confounders within pairs before randomization; subsequently, one 
cluster from each pair was randomly assigned to the less intensive arm, the other to the more 
intensive arm. The balance of potential confounders was examined, and unbalanced 
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randomizations were discarded, followed by re-randomization. The process was continued until 
balance in measured characteristics was achieved. These characteristics included the annual 
volume of chest CT scanning; integrated vs. non-integrated setting; KPSC vs. other institutions; 
distribution of race/ethnicity; distribution of smoking; inclusion of patients with screening-
detected nodules; timing of notification letters to participants; frequency of using positron 
emission tomography for nodule characterization; and distribution of insurance type. 
Ultimately, 24 sites were randomly assigned evenly to two groups; one non-enrolling site was 
replaced by an alternative in month 18 of the enrollment period. KPSC medical centers were 
treated as separate clusters because they are relatively large in size and sufficiently 
independent in their operations to enable use of different surveillance protocols at the medical 
center level. The larger number of clusters is important because statistical power depends 
partly on the total number of clusters.
Participants
The target population includes adults ≥35 years-old with small pulmonary nodules detected 
either incidentally or by screening and measuring ≤15 mm in widest diameter that are judged 
by the interpreting radiologist to require subsequent evaluation or surveillance for possible 
cancer. Interpreting radiologists were encouraged not to enroll patients with nodules judged 
likely to be benign, such as those with a benign pattern of calcification, intranodular fat or a 
location and morphology that are typical for an intrapulmonary lymph node.(21) In addition, 
radiologists were advised not to enroll most patients with associated pulmonary abnormalities 
such as pleural effusions, atelectasis, or lymphadenopathy (which increase the risk of lung 
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cancer), as they would need immediate and more aggressive evaluation, and not to enroll 
patients with multiple pulmonary nodules that are thought to be more consistent with infection 
or inflammation. However, enrollment was ultimately at the radiologist’s discretion.
Exclusion criteria include: age <35 years; nodule identified on prior chest CT scan within 
2 years; prior history of pulmonary or extrapulmonary cancer within the past 5 years (except for 
non-melanoma skin cancer); and pregnancy within 9 months before nodule identification. 
Enrollment
Eligible patients are enrolled passively by the clinical radiologist at the time of image 
interpretation. Concurrently, the radiologist delivers the study intervention by inserting 
recommendations for evaluation in the dictated radiology report. Patients are flagged for 
possible inclusion and enrollment using methods tailored to fit each site. While some sites 
identify eligible patients by manually reviewing radiology transcripts, other sites are using 
automated methods, including insertion of unique text strings, hashtags or tracking 
assignments into dictated reports, or the use of a novel desktop application designed to 
facilitate enrollment and data collection. Sites were encouraged to customize these methods to 
be compatible with existing workflow. 
Interventions
To compare the effectiveness of existing strategies for pulmonary nodule surveillance, the 
protocols for more intensive and less intensive surveillance were based on published guidelines 
(Tables 2 and 3).(5-7, 9) For patients with nodules detected incidentally, the study protocols 
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were based on a comparison of the (more intensive) original Fleischner Society 
recommendations(5, 7) with the (generally less intensive) revised Fleischner Society 
recommendations.(6) Ranges for follow-up times were simplified to maximize differences 
between study arms; for example, a recommendation for follow-up in 3 to 6 months was 
converted to 3 months in the more intensive arm and 6 months in the less intensive arm. For 
screening-detected nodules, the final protocols were based on a comparison of Lung-RADS 
recommendations (less intensive) with a more intensive set of recommendations based on the 
original Fleischner Society guidelines, mapped to Lung-RADS categories.(9) For example, in the 
more intensive arm, the recommendation for a Lung-RADS category 2 finding is to repeat the 
CT scan in 6 months (instead of 12 months), while the recommendation for a Lung-RADS 
category 3 finding is to repeat the CT scan in 3 months (instead of 6 months). Of note, while 
both Lung-RADS and the original Fleischner Society recommendations were considered by the 
study investigators and stakeholders to represent the de facto standards of care, they were 
judged to be based on low quality evidence, because there are no prior randomized trials or 
observational studies that compared two or more protocols for nodule surveillance. The newly 
revised and less intensive recommendations from the Fleischner Society were judged to be in 
need of evaluation, because they had not yet been implemented in most practice settings and 
had not been subjected to clinical experience.
Outcomes
Study outcomes were selected based on iterative rounds of feedback from both patient and 
non-patient stakeholders (Table 4), including a range of clinical, patient-centered and health 
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system outcomes. The primary study outcome (Aim 1) is tumor progression beyond AJCC 7th 
edition stage T1aN0M0 (tumor size ≤20 mm), the stage with the most favorable prognosis. This 
size threshold was identified as the best cut-point for discrimination of survival by the staging 
project of the International Association for the Study of Lung Cancer.(13) This corresponds to 
progression beyond stage T1bN0M0 in the newer AJCC 8th edition.(22) The primary outcome 
will be ascertained by linking study records with data from state cancer registries. Secondary 
cancer-related outcomes include time to cancer diagnosis and overall survival, both measured 
from the date of the index chest CT scan.
Patient-centered outcomes (Aim 2) will be ascertained by completion of web-based 
surveys approximately 1-2 months, 13 months and 25 months following the index chest CT 
scan. Outcomes of interest include: nodule-related emotional distress, measured with the 22-
item Impact of Event Scale;(23) anxiety, measured using the 6-item State-Trait Anxiety 
Inventory;(24) and a single-item question about general health status. Patient surveys also 
include questions about patient satisfaction with the process of lung nodule surveillance, 
provider communication, preferred style of decision-making and barriers to adherence with 
follow-up. 
Participating radiologists and ordering providers will complete novel surveys to assess 
knowledge, attitudes and beliefs about existing guidelines for pulmonary nodule evaluation (at 
baseline) and the assigned protocols for surveillance in use at their site (near the end of 
enrollment). 
Nodule-related resource utilization (Aim 3) will be ascertained by searching structured 
data in the EHR for relevant Current Procedural Terminology (CPT) and International 
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Classification of Disease, version 10 (ICD-10) procedure codes that appear during the 
surveillance period (from date of the index CT scan to the date of cancer diagnosis or 2 years of 
follow-up, whichever comes first). We will capture all nodule-related imaging tests (chest CT, 
positron emission tomography, bone scans, brain CT or magnetic resonance imaging, 
abdominal and pelvic CT), invasive biopsy procedures (bronchoscopy, transthoracic needle 
biopsy), thoracic surgical procedures, emergency department visits and hospitalizations. We 
will also record procedure-related complications by searching for diagnostic codes for contrast-
induced nephropathy, pneumothorax, respiratory failure and major bleeding.
Outcomes for Aim 3 also include radiation exposure, as reflected by the computed 
tomography dose index (CTDIvol), the dose-length product (DLP), and the effective radiation 
dose. The CTDIvol equals the average dose emitted by the scanner within each small area 
imaged (often called a slice), while the DLP represents the total imparted radiation and is 
defined as the CTDIvol multiplied by the scan length. Effective dose is a calculated value and is a 
function of the DLP, the specific organs irradiated, and the sensitivity of the organs irradiated to 
develop cancer in the future. Effective dose will be calculated using DLP and established 
conversion formulas.(25)
Aim 4 will compare adherence to the assigned surveillance protocol at the level of the 
interpreting radiologist, the ordering provider, and the individual patient. The primary measure 
of adherence will be adherence with the first recommended surveillance test: was the test 
recommended by the radiologist, ordered by the provider, and completed by the patient? 
Secondary analyses will examine more granular information about adherence on a test-by-test 
basis and pinpoint the level of non-adherence. 
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Data Collection and Management
Data elements will be collected and managed locally by investigators at each site, and 
subsequently transferred securely to the Data Coordinating Center (DCC) at UC Davis for quality 
control and analysis. EHRs will be searched for information on baseline patient characteristics 
(e.g. demographics, smoking status, comorbid conditions) and health care utilization. Radiology 
reports will be searched manually and/or by using validated natural language processing 
algorithms to ascertain nodule size, attenuation (solid, part-solid or non-solid), location, 
calcification and edge characteristics. Survey data will be collected locally or centrally by the 
DCC, depending on the site. Patient surveys will not be distributed at one of the sites 
(Vanderbilt University). To ascertain the primary outcome (cancer diagnosis and stage), linkages 
will be made with data from state cancer registries either centrally by the DCC, or locally at 
selected health care systems. All sites are required to conduct monthly quality assurance by 
manually reviewing random samples of dictated radiology reports to ensure appropriate 
enrollment of eligible patients. The study is overseen by an independent Data Safety and 
Monitoring Board.
Statistical Power
The study was designed to demonstrate the non-inferiority of the less intensive surveillance 
protocol relative to the more intensive protocol. With a sample size of 960 individuals with 
cancerous nodules, the study will have 90% power to demonstrate non-inferiority with a 
margin of 5% for the primary outcome of cancer progression beyond stage T1a, using a one-
sided Z test with a significance level of 0.05 and an intraclass correlation coefficient (ICC) of 
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0.012. The non-inferiority margin was selected by members of the research team in 
collaboration with clinical and patient stakeholders to be the narrowest possible margin that 
allowed for a feasible sample size. Assuming 3% of enrolled patients with nodules measuring 
≤15 mm will have cancer, and allowing for a 10% loss to follow-up, the trial will require 
enrollment of 35,200 participants to meet the target sample size. Alternatively, if the ICC is 
≤0.01, the study will still have 90% power to demonstrate non-inferiority with 888 cancerous 
nodules (or 32,560 participants enrolled).
Statistical Analysis
The primary analysis will evaluate whether less intensive surveillance is non-inferior to more 
intensive surveillance by examining the upper bound of the 95% confidence interval (CI) for the 
difference in percentage for the less-intensive surveillance vs. more-intensive surveillance. The 
null hypothesis is that less intensive surveillance is inferior to more intensive surveillance, i.e., 
the less intensive arm will result in 5 percentage-points or more of tumors progressing beyond 
stage T1aN0M0 than the more intensive arm. We will reject this null-hypothesis and conclude 
that less intensive surveillance is non-inferior to more intensive surveillance if the upper bound 
of the 95% CI for the difference of the percentages of patients with tumor progression beyond 
T1aN0M0 if the less vs. more intensive arm does not exceed the non-inferiority margin of 5%. 
We will model the primary outcome using hierarchical logistic regression, including random 
site-specific effects to account for clustering of patients within sites. Hierarchical logistic 
regression models will be fitted without (primary analysis) and with (secondary analysis) 
adjusting for potential confounders including age, gender, ethnicity/race, smoking, body mass 
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index, baseline nodule size, indication for CT (screening or diagnostic), and all facility-level 
factors balanced during the randomization. The difference in adjusted percentages of patients 
with tumor progression beyond T1aN0M0 will be estimated using predictive margins, averaging 
over the predicted values for each site and standardizing to the overall study population for 
models adjusting for potential confounders.(26, 27)
Primary analyses will be by intention to treat (ITT), including all patients with qualifying 
nodules, including those who do not undergo surveillance (i.e., non-adherent cases or patients 
that proceed directly to tissue diagnosis). We will perform a per protocol (PP) sensitivity 
analysis to evaluate outcomes by surveillance strategy received.
Pre-specified subgroup analyses will include interaction terms to evaluate whether 
outcomes vary by indication (lung cancer screening vs. other), smoking history, nodule density 
(solid, part-solid, or non-solid), health care setting (integrated vs. other), demographic 
characteristics (age, sex, race/ethnicity), and geographic region (endemic for mycosis vs. non-
endemic). For interactions significant at the 0.20 level, we will explore the treatment effects in 
corresponding subgroups. We will use multiple imputation to account for missing data. 
Human Subjects
The study protocol was approved by the Institutional Review Board (IRB) at each participating 
site. In all cases, the IRB granted a waiver of informed consent because the study is testing a 
system-level intervention (insertion of guideline-based recommendations for surveillance), and 
because the risks of participating in this comparative effectiveness study were judged to be no 
different than the risks commonly encountered in usual clinical practice.(28, 29) In addition, the 
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study would not be feasible or logistically possible without the waiver, because the intervention 
(insertion of recommendations) is delivered by the interpreting radiologist during usual clinical 
workflow at the time of interpretation, which typically occurs long after the patient has been 
discharged from the radiology department. Of note, patients, radiologists and ordering 
providers are permitted to deviate from the recommendations when dictated by patient 
preference or clinical judgment. Although the requirement for informed consent was waived, 
most sites decided in collaboration with their IRB to contact enrolled participants by letter or 
electronic mail to notify them about the study and provide an opportunity to opt-out for data 
collection purposes. Participants who completed surveys provided consent electronically online 
or by phone for this portion of the study.
Study Team and Governance
The study team includes researchers, clinicians, patients and additional stakeholders from 
professional societies and advocacy groups (Figure 2). All collaborative activities are guided by 
the PCORI engagement principles of reciprocity, co-learning, partnership, trust, transparency 
and honesty.(30) Both patient and non-patient stakeholders have actively participated in the 
design and execution of the trial and have vetted and endorsed all major decisions, including 
the design of the surveillance protocols, the selection of outcomes and the methods used to 
passively enroll and subsequently notify study participants.
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Discussion
Watch the Spot is a large, unblinded, pragmatic, cluster-randomized, non-inferiority, 
comparative effectiveness trial that addresses an important gap in what is known about the 
evaluation and management of patients with small pulmonary nodules. Current guidelines for 
patients with nodules detected either incidentally or by screening are not based on evidence 
from randomized controlled trials or well-designed observational studies of comparative 
effectiveness. Despite this, hundreds of thousands of individuals each year undergo lung nodule 
follow-up that may represent either too much or too little care.(3) 
By comparing existing guidelines for pulmonary nodule surveillance, the results of 
Watch the Spot will set the bar for the frequency and duration of nodule follow-up. If less 
intensive surveillance is shown to be non-inferior to more intensive care, the study will provide 
high quality evidence in support of using the revised Fleischner Society guidelines and the 
current Lung-RADS recommendations. If non-inferiority is not demonstrated, the trial will send 
a strong signal that the original, more intensive, Fleischner Society recommendations should be 
reinstated (and that Lung-RADS recommendations should be intensified). Similarly, if patient 
satisfaction and adherence are found to be suboptimal, this might prompt efforts to modify 
existing guidelines and address any barriers to adherence that we identify.
One important limitation of this comparative effectiveness trial is that the interventions 
to be compared were necessarily limited to existing guidelines, and we therefore were not able 
to include a simpler protocol for nodule surveillance. Given the pragmatic design and our focus 
on comparative effectiveness, it was paramount to compare strategies used in current clinical 
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practice, including one strategy thought to represent the de facto standard of care and another 
one based on newly revised yet untested recommendations from a respected professional 
society. In addition to ensuring equipoise between the study arms, the protocols were designed 
to be acceptable to practitioners and relevant to clinical and policy-level decision-making. At 
the same time, the two protocols were implemented in a way that made them as distinct as 
possible to enable us to find true differences in outcomes, if they exist. 
Another limitation is that the planned ITT analysis will be biased to the null (non-
inferiority) if there is poor adherence with the surveillance recommendations.(31) However, 
analysis by ITT is preferred because the goal of the trial is to compare the real-world 
effectiveness of strategies for surveillance of small pulmonary nodules, rather than efficacy 
under the more idealized assumptions of the PP analysis.(32) ITT preserves the benefits of 
cluster randomization, maintains sample size, prevents bias in analyses resulting from post-
randomization exclusion, and has been widely used in non-inferiority trials.(33) In addition, 
results can be biased in either direction for both ITT and PP analyses.(34) In one recent review 
article, the authors found that the method of analysis seldom affected the results, and the ITT 
analysis was actually more conservative in four out of five trials.(35) Thus, we favor ITT as the 
primary analysis to compare the real-world effectiveness of two surveillance strategies in this 
pragmatic, cluster-randomized, non-inferiority trial. In contrast, the PP sensitivity analysis will 
address the policy-relevant question of efficacy under the assumption of perfect adherence.
A final limitation is uncertainty about the magnitude of the intraclass correlation 
coefficient and the prevalence of malignant nodules that could result in reduced statistical 
power.    
Page 17 of 33  ANNALSATS Articles in Press. Published on 17-July-2019 as 10.1513/AnnalsATS.201903-268SD 
 Copyright © 2019 by the American Thoracic Society 
Watch the Spot has several novel and distinctive features of interest to clinicians, clinical 
trialists and funders of research. Foremost, it is one of the first large, pragmatic clinical trials to 
be funded by PCORI. The overarching goal of the pragmatic design was to integrate study 
procedures into usual clinical care to the greatest extent possible, to maximize both the 
efficient use of resources and the generalizability of our findings. Second, the use of cluster-
randomization and the evaluation of an intervention applied at the system-level are relatively 
uncommon in comparative effectiveness research, although countless other diagnostic and 
therapeutic protocols are potentially amenable to system-level implementation and evaluation. 
Third, the study protocol enables sites to customize methods for identifying and (passively) 
enrolling participants. Most sites employ largely automated approaches, illustrating the 
potential efficiency gains of technology-enabled research. Assuming the study reaches its 
enrollment target of approximately 35,200 participants, the cost per patient enrolled will be 
only $250, a small fraction of the per patient cost of a conventional randomized clinical trial. 
Lastly, the design and execution of the study are the product of intensive engagement with 
patient and non-patient stakeholders, ensuring that the study reflects the values and 
preferences of all concerned stakeholders, and is responsive to the information needs of 
patients with pulmonary nodules and the clinicians who care for them.
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Figure Legends
Figure 1: Schematic representation of study design. Fleischner= Fleischner Society 
recommendations for pulmonary nodule evaluation. Lung-RADS= Lung Imaging Data and 
Reporting System.
Figure 2: Governing structure. The study is led by the Principal Investigators, in collaboration 
with the Stakeholder Advisory Group and the Steering Committee. All decisions are made by 
the Executive Committee, after formal vetting and approval by the Steering Committee and 
Stakeholder Advisory Group. Additional Work Groups are charged with project management, 
data management and survey development. Local study teams at each site identify and enroll 
participants and have primary responsibility for secure data collection, storage and transfer to 
the Data Coordinating Center.
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Participating Clinical Institutions
Site PIs 
Co-Investigators 
Project Managers 
Data Managers 
Clinical Champions 
Operational Leaders 
Patient Representatives 
Research Assistants 
Stakeholders
Committees Composition Meeting Frequency
Executive Committee (EC) Research leadership (study PIs), Data Coordinating Center 
representatives, 1 site PM 
Weekly 
Stakeholder Advisory Group
(SAG) 
Research leadership (study PIs), all patient and non-patient
stakeholder partners 
Quarterly 
Steering Committee (SC) Research leadership (study PIs), all site PIs, 1 patient 
partner, 2 non-patient partners
Monthly 
Project Manager Workgroup All site PMs, site research support staff Monthly 
Local Study Teams (LST) Site PI, Clinical champions, operational or administrative
leader, local patient representative
Varies depending on
site
Provider and Patient Survey 
Workgroup
Research leadership (study PIs), interested site PIs, site Co-
Investigators, site PMs, and interested stakeholders 
Bi-weekly, then as 
needed  
Patient Partners 
Non-patient Partners 
• Professional Societies 
• Advocacy Groups 
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Table 1: Description of Study Sites
*Kaiser Permanente Southern California hospitals assigned to more intensive surveillance 
include facilities in Downey, Fontana, Panorama City, Riverside and San Diego. Hospitals 
assigned to the less intensive group include those located in Baldwin Park, Los Angeles, Orange 
County, South Bay, West Los Angeles and Woodland Hills.
Health Care Organization Geographic Location
Presence 
of 
Endemic 
Mycosis
Will Enroll 
Patients 
with 
Screen-
Detected 
Nodules
Type of 
System
Group 
Assign-
ment 
(More vs. 
Less 
Intensive)
Boston Medical Center Northeast No No Safety Net More
Cleveland Clinic Northeast Yes No Referral Less
Health Partners, MN Midwest Yes Yes Integrated More
Kaiser Permanente Colorado Mountain West
No Yes Integrated Less
Kaiser Permanente Northwest Northwest No Yes Integrated Less
Kaiser Permanente Southern 
California
Southwest Yes Yes Integrated Both*
Medical University of South 
Carolina
Southeast Yes Yes University More
National Jewish Health Mountain West
No No Referral More
Portland Veterans Affairs Med 
Center
Northwest No Yes Integrated Less
University of California Davis West Yes Yes University Less
University of California Los Angeles Southwest Yes No University More
University of California San 
Francisco
West No No University Less
University of Pennsylvania Northeast No No University More
Vanderbilt University Southeast Yes No University More
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 Table 2a: Study protocol for surveillance or evaluation of solid nodules, Group A
Size (mm) Incidental Nodule in 
Patient without Risk 
Factors (follow-up in 
months)
Incidental Nodule in 
Patient with Risk 
Factors (follow-up in 
months)
Screening-Detected 
Nodule (follow-up in 
months)
≤4 Optional at 12 12 12, 24…
>4 to ≤6 12 6, 18 6, 18, (30)
>6 to ≤8 6, 18 3, 9, 21-24 3, 15, 27…
>8 PET, biopsy or CT at 3, 9, 21-24 months
Recommendations for incidentally detected solid nodules based on Fleischner Society 
guidelines (2005). Recommendations for solid nodules detected by screening adapted from the 
Lung CT Screening Reporting and Data System (Lung-RADS). Numbers in parentheses reflect 
follow-up that may occur after the study is over. Ellipsis indicates that annual screening should 
continue until patient no longer meets eligibility criteria.
Table 2b: Study protocol for surveillance or evaluation of sub-solid nodules, Group A
Attenuation Size (mm) Size of Solid 
Component (mm)
Patient with or without Risk 
Factors (follow-up in months)
≤5
Incidental and solitary: None
Incidental and multiple: 24, (48)
Screening-detected: 12, 24…Non-Solid
>5 3, 15, 27, (39)
Any <5 3, 15, 27, (39)
Part-Solid Any ≥5 Repeat CT at 3 months; if persistent, biopsy or resect
Recommendations for incidentally detected sub-solid nodules based on Fleischner Society 
guidelines (2013). Recommendations for sub-solid nodules detected by screening adapted from 
the Lung CT Screening Reporting and Data System (Lung-RADS). Numbers in parentheses reflect 
follow-up that may occur after the study is over. Ellipsis indicates that annual screening should 
continue until patient no longer meets eligibility criteria.
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Table 3a: Study protocol for surveillance or evaluation of solid nodules, Group B
Size (mm) Incidental Nodule in 
Patient without Risk 
Factors (follow-up in 
months)
Incidental Nodule in 
Patient with Risk 
Factors (follow-up in 
months)
Screening-Detected 
Nodule (follow-up in 
months)
<6 None Optional at 12 12, 24…
Solitary: 12, 24 12, 24…≥6 to ≤8 Multiple: 6, 18 6, 18, (30)…
>8 PET, biopsy or CT at 3, 15, (27) months
Recommendations for incidentally detected solid nodules based on Fleischner Society 
guidelines (2017). Recommendations for solid nodules detected by screening based on the Lung 
CT Screening Reporting and Data System (Lung-RADS). Numbers in parentheses reflect follow-
up that may occur after the study is over. Ellipsis indicates that annual screening should 
continue until patient no longer meets eligibility criteria.
Table 3b: Study protocol for surveillance or evaluation of sub-solid nodules, Group B
Attenuation Size (mm) Incidental Nodule in Patient 
with or without Risk Factors 
(follow-up in months)
Screening-Detected 
Nodule (follow-up in 
months)
<6 Solitary: NoneMultiple: 6, 24, (48)Non-Solid
≥6 Solitary: 12, (36), (52)Multiple: 6, 24, (48)
<6 Solitary: NoneMultiple: 6, 24, (48)
Solitary: 12, 24…
Multiple: 6, 18, (30)…
Part-Solid
≥6 6, 18, (30), (42), (54), (66); biopsy if solid component ≥6 6, 18, (30)…
Recommendations for incidentally detected sub-solid nodules based on Fleischner Society 
guidelines (2017). Recommendations for sub-solid nodules detected by screening based on the 
Lung CT Screening Reporting and Data System (Lung-RADS). Numbers in parentheses reflect 
follow-up that may occur after the study is over. Ellipsis indicates that annual screening should 
continue until patient no longer meets eligibility criteria.
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Table 4: Definitions and source information for outcomes, by specific aim
Aim Sample Outcome Definition Source
AJCC 7 Stage 
>T1aN0M0
Tumor size >20 mm at time of 
resection or radiotherapy, with 
no distant metastasis or regional 
lymph node involvement.
Time to 
treatment
Time to surgery, radiotherapy or 
chemotherapy, measured from 
date of index CT scan to date of 
first treatment.
1 Participants 
with cancerous 
nodules
Survival Measured from date of index CT 
scan to death or censoring.
Cancer 
Registry, EHR
Nodule-related 
distress
Measured with validated Impact 
of Event Scale (IES-R). 
Assessments performed 1-2 
months after index CT scan, at 
13 months, and at end of follow-
up. 
Anxiety Measured with validated State-
Trait Anxiety Inventory (STAI-6). 
Assessments performed 1-2 
months after index CT scan, at 
13 months, and at end of follow-
up.
General health 
status
Measured with 1 item from the 
validated Short Form Health 
Survey. Assessments performed 
1-2 months after index CT scan, 
at 13 months, and at end of 
follow-up.
Smoking 
history
Measured with items selected 
from the Cancer Care Outcomes 
Research and Surveillance Study 
patient survey.  Assessments 
performed 1-2 months after 
index CT scan, at 13 months, and 
at end of follow-up.
Health literacy Measured with the validated 
Single Item Literacy Screener. 
Assessment performed 1-2 
months after index CT scan.
2 All patients with 
nodules and 
access to email
Perceived Measured with items adapted 
Self-
administered 
web survey
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susceptibility 
to cancer
from the validated Champion 
Health Belief Model Tool. 
Assessment performed 1-2 
months after index CT scan.
Cancer worry Measured with an item adapted 
from the validated Lerman 
Cancer Worry Scale. Assessment 
performed 1-2 months after 
index CT scan. Measured with 
novel items at 13 months, and at 
end of follow-up.
Patient 
preferences 
about control 
over decision 
making
Measured with an adapted 
version of the validated Control 
Preferences scale. Assessments 
performed 1-2 months after 
index CT scan, at 13 months, and 
at end of follow-up.
Motivation to 
quit smoking
Measured with items adapted 
from Sciamanna et al.(36) 
Assessments performed with 
self-reported smokers at 1-2 
months after index CT scan, at 
13 months, and at end of follow-
up.
Perceived risks 
and benefits of 
lung nodule 
surveillance
Measured with items adapted 
from the validated Decisional 
Conflict Scale.(37)  Assessments 
performed 1-2 months after 
index CT scan, at 13 months, and 
at end of follow-up.
Concrete 
barriers to lung 
nodule 
surveillance
Measured with novel items, 
Likert-type scale.  Assessments 
performed 1-2 months after 
index CT scan, at 13 months, and 
at end of follow-up.
Provider 
communication 
about lung 
nodule 
surveillance
Measured with novel items, 
Likert-type scale. Assessments 
performed 1-2 months after 
index CT scan, at 13 months, and 
at end of follow-up.
Satisfaction 
with evaluation
Measured with novel items, 
Likert-type scale. Assessment 
performed at 13 months and at 
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the end of follow-up.
All participating 
radiologists, 
ordering 
providers 
(pulmonologists, 
thoracic 
surgeons, and 
PCPs)
Knowledge, 
attitudes, and 
beliefs about 
guidelines and 
practices for 
lung nodule 
evaluation; 
satisfaction 
with 
surveillance 
protocol and 
notification 
systems; 
organizational 
factors 
affecting 
adherence
Measured with novel items 
based on the Consolidated 
Framework for Implementation 
Research, Likert-type scale. 
Assessments performed within 1 
– 2 months of trial launch and at 
18 months after trial launch. 
Self-
administered 
web or paper-
based survey
3 All patients with 
nodules
Nodule-related 
resource 
utilization and 
total radiation 
exposure
Includes all CT scans; PET scans; 
other imaging tests; invasive 
biopsy procedures 
(bronchoscopic and 
percutaneous); thoracic surgical 
procedures; all outpatient visits, 
ED visits and hospitalizations 
during the surveillance period.
EHR
4 All patients with 
nodules, 
random 10% 
sample for 
greater detail
Adherence 
with assigned 
surveillance 
protocol
EHR reviewed to determine 
whether surveillance imaging 
was completed per protocol; 
detailed review of radiology 
transcripts and orders to 
determine whether assigned 
protocol was recommended by 
radiologist and ordered by 
provider.
EHR, 
radiology 
transcripts
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Online Data Supplement
Methods for the Watch the Spot Trial: A Pragmatic Trial of More vs. Less Intensive Strategies 
for Active Surveillance of Small Pulmonary Nodules
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Appendix A: Watch the Spot Settings and Investigators 
Kaiser Permanente Southern California: Michael Gould (PI), Brian Mittman (co-I), Danielle 
Altman, Beth Creekmur, Brian Huang, Chengyi Zheng, Visanee Musigdilok, Emily Rozema
Boston Medical Center: Renda Wiener (co-I), Anuradha Rebello, Hasmeena Kathuria, Karen 
Lasser, Linda Rosen, Vruti Virani
Cleveland Clinic: Peter Mazzone (co-I), Amy Pritchard, Ruffin Graham, Sudish Murthy, Joseph 
Azok, Christopher Estling
HealthPartners: Charlene McEvoy (co-I), Linda Loes, Mary T. Becker, Angela Tai
Kaiser Permanente Colorado: Debra P. Ritzwoller (co-I), Christina Clarke, Julie Steiner, Ruth 
Bedoy, Courtney Kraus, Caroline Joyce
Kaiser Permanente Northwest: Eric Walter (co-I), Anne Ramey, Catherine Cleveland, Jennifer 
Cook, Britta Torgrimson-Ojero, and Deralyn Almaguer
Medical University of South California: Gerard Silvestri (co-I), James Ravenel, Kate Taylor, Katie 
Kirchoff, Nichole Tanner
National Jewish Health: Debra Dyer (co-I), Elizabeth Kern, Pearlanne Zelarney
University of Pennsylvania: Anil Vachani (co-I), Eduardo Barbosa, Jennifer Steltz
University of California, Davis, School of Medicine, Department of Public Health Sciences: 
Diana Miglioretti (co-I), Evan de Bie, Lihong Qi, Yang Vang 
University of California, Davis, School of Medicine, Department of Medicine: Karen Kelly (co-I), 
Friedrich Knollmann, Diem Le, Shantha Rao
University of California, Los Angeles: Denise Aberle (co-I), Chang Su, Igor Barjaktarevic
University of California, San Francisco: Rebecca Smith-Bindman (co-I), Sophronia Yu
Veterans Affairs Portland Health Care System: Christopher Slatore (co-I), Sara Golden, Danielle 
Apodaca, Sarah Shull, Matthew Howard
Vanderbilt University Medical Center: Kim Sandler (co-I), Emily Epstein, Karthik Ramadass
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Appendix B: Watch the Spot Stakeholders
Patient stakeholders
Jamie Daniel
Kathleen Fennig
Charles Florsheim 
Kaitlyn Pedotti
Non-patient stakeholders and their affiliations
Jill Arnstein, American Lung Association in California
Frank Detterbeck, American College of Chest Physicians
Ella A. Kazerooni, American College of Radiology & National Lung Cancer Roundtable
Amy Moore, Bonnie J. Addario Lung Cancer Foundation
Richard Mularski, The COPD Patient Powered Research Network of the COPD Foundation
Nir Peled, International Association for the Study of Lung Cancer, Soroka Cancer Center and 
Ben-Gurion University, Beer Sheva, Israel
Charles Powell, American Thoracic Society
Robert Smith, American Cancer Society
Laszlo T. Vaszar, Mayo Clinic Arizona 
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